Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 20 of 20 entries
View as:

F901318 Single Ascending Dose Study in Healthy Male Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02142153 Org: User:
Start: 08/31/14 End: 10/31/14 Due: 10/31/15

Pharmacokinetics of IV Formulation

Phase: N/A Priority: Normal
NCT ID: NCT03076905 Org: User:
Start: 05/31/17 End: 08/31/17 Due: 08/31/18

Single Ascending Oral Dose Study of F901318

Phase: N/A Priority: Normal
NCT ID: NCT02394483 Org: User:
Start: 10/31/15 End: 09/30/16 Due: 09/30/17

A Phase I Study to Assess the Pharmacokinetics of Olorofim in Subjects With Renal Impairment

Phase: N/A Priority: Normal
NCT ID: NCT05200286 Org: User:
Start: 02/10/22 End: 12/13/22 Due: 12/13/23

A Biopharmaceutics Study to Assess the Pharmacokinetics of Single Oral and IV Doses of Olorofim

Phase: N/A Priority: Normal
NCT ID: NCT04207957 Org: User:
Start: 12/05/19 End: 09/15/20 Due: 09/15/21

Radiolabelled IV and Oral Metabolism Study of F901318

Phase: N/A Priority: Normal
NCT ID: NCT02912026 Org: User:
Start: 05/31/19 End: 07/31/19 Due: 07/31/20

Safety and Pharmacokinetics of Oral F901318 (Fluconazole and Posaconazole) IN Aml Leukaemia

Phase: N/A Priority: Normal
NCT ID: NCT03036046 Org: User:
Start: 03/31/17 End: 03/31/18 Due: 03/31/19

Evaluation of Immediate Release Tablet

Phase: N/A Priority: Normal
NCT ID: NCT02808741 Org: User:
Start: 07/31/16 End: 11/30/16 Due: 11/30/17

Study of Potential for Interaction of Fluconazole With F901318

Phase: N/A Priority: Normal
NCT ID: NCT02730442 Org: User:
Start: 02/29/16 End: 06/30/16 Due: 06/30/17

Drug-drug Interaction (DDI) Study to Assess Effect of Itraconazole and Rifampicin Upon Olorofim

Phase: N/A Priority: Normal
NCT ID: NCT04171739 Org: User:
Start: 11/18/19 End: 02/11/20 Due: 02/11/21

Olorofim Aspergillus Infection Study

Phase: N/A Priority: Normal
NCT ID: NCT05101187 Org: User:
Start: 03/31/22 End: 11/01/26 Due: 11/01/27

Multiple Ascending Oral Dose Study of F901318 in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02737371 Org: User:
Start: 05/31/16 End: 05/22/17 Due: 05/22/18

Drug/Drug Interactions With F901318

Phase: N/A Priority: Normal
NCT ID: NCT03095547 Org: User:
Start: 05/31/17 End: 10/31/17 Due: 10/31/18

F901318 Multiple Ascending Dose Study

Phase: N/A Priority: Normal
NCT ID: NCT02342574 Org: User:
Start: 02/28/15 End: 09/30/16 Due: 09/30/17

Absorption, Metabolism and Excretion of 14C-olorofim in Man

Phase: N/A Priority: Normal
NCT ID: NCT04039880 Org: User:
Start: 07/30/19 End: 09/30/19 Due: 09/30/20

A Phase I Study to Assess the Pharmacokinetics of Olorofim in Subjects With Hepatic Impairment

Phase: N/A Priority: Normal
NCT ID: NCT04752540 Org: User:
Start: 07/02/21 End: 10/24/21 Due: 10/24/22

Evaluate F901318 (Olorofim) Treatment of Invasive Fungal Infections in Participants Lacking Treatment Options

Phase: N/A Priority: Normal
NCT ID: NCT03583164 Org: User:
Start: 06/06/18 End: 02/10/23 Due: 02/10/24

Study on Safety and Pharmacokinetics of Intravenous F901318 for Fungal Prophylaxis in AML Patients

Phase: N/A Priority: Normal
NCT ID: NCT02856178 Org: User:
Start: 04/20/17 End: 04/20/17 Due: 04/20/18

Evaluation of the Potential for Cytochrome P450 3A4 Inhibition by F901318 Using Oral Midazolam as a Probe

Phase: N/A Priority: Normal
NCT ID: NCT02680808 Org: User:
Start: 01/31/16 End: 06/30/16 Due: 06/30/17

Assessment of Varying Oral Dosing Regimens for F901318 in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT03340597 Org: User:
Start: 12/12/17 End: 04/13/18 Due: 04/13/19